PIK3CD and osteosarcoma: Apart from the commonly affected TP53 and RB1 pathways in osteosarcoma, Perry et al. [47] reported genomic alterations in the PI3K/mTOR pathway in a full 24% of cases in their cohort, highlighting potential therapeutic targetability thereof.